P. Andrews

发表

Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function

Y. Xiong, P. Andrews, Y. He, 2006, Oncogene.

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.

Steve Schneider, Xin Huang, John Newcomb, 2013, Journal of medicinal chemistry.

Development of a homogeneous AlphaLISA ubiquitination assay using ubiquitin binding matrices as universal components for the detection of ubiquitinated proteins.

P. Andrews, Steve Schneider, R. Emkey, 2012, Biochimica et biophysica acta.

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.

T. Bush, A. Cheng, D. Whittington, 2011, Bioorganic & medicinal chemistry letters.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

H. Bregman, J. Newcomb, P. Andrews, 2013, Journal of medicinal chemistry.

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

Xin Huang, Klaus Michelsen, Michael D Bartberger, 2009, Journal of medicinal chemistry.

Drosophila Morgue is an F box/ubiquitin conjugase domain protein important for grim-reaper mediated apoptosis

L. Schwartz, P. Andrews, K. White, 2002, Nature Cell Biology.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Karina Romero, Renee Emkey, Hao Chen, 2012, Journal of medicinal chemistry.

Ubiquitin Ligase Substrate Identification through Quantitative Proteomics at Both the Protein and Peptide Levels

T. Mustelin, R. Black, P. Andrews, 2011, The Journal of Biological Chemistry.

Comparison of 2 Cell-Based Phosphoprotein Assays to Support Screening and Development of an ALK Inhibitor

P. Andrews, R. Emkey, R. Brake, 2011, Journal of biomolecular screening.

Virtual screening to identify potent sepiapterin reductase inhibitors.

P. Andrews, Xin Huang, Steve Schneider, 2019, Bioorganic & medicinal chemistry letters.

Pharmacological Assessment of Sepiapterin Reductase Inhibition on Tactile Response in the Rat

P. Andrews, W. McCarty, Steve Schneider, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Special Section on The Opioid Crisis Pharmacological Assessment of Sepiapterin Reductase Inhibition on Tactile Response in the Rat s

P. Andrews, W. McCarty, Steve Schneider, 2019 .

Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.

P. Andrews, Steve Schneider, R. Emkey, 2010, Assay and drug development technologies.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

T. Bush, A. Cheng, P. Andrews, 2012, Bioorganic & medicinal chemistry letters.

Abstract 1795: Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase

D. Whittington, P. Andrews, K. Wilcoxen, 2012 .

Assays for RING family ubiquitin ligases.

Y. Xiong, P. Andrews, M. Furukawa, 2005, Methods in molecular biology.